Arginase enzymes in isolated airways from normal and nitric oxide synthase 2-knockout mice exposed to ovalbumin

Toxicology and Applied Pharmacology

Volumn 234, Issue 3, 2009, Pages 273-280

  Bratt, Jennifer M ^a   Franzi, Lisa M ^a   Linderholm, Angela L ^a   Last, Michael S ^a   Kenyon, Nicholas J ^a   Last, Jerold A ^a  

^a CCRBM   (United States)

Author keywords

Airway hyperreactivity; Airway inflammation; Animal model; Asthma; Eosinophils; Nitric oxide

Indexed keywords

ARGINASE; ARGINASE 1; ARGINASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; N(G) HYDROXYARGININE; OVALBUMIN; UNCLASSIFIED DRUG;

AEROSOL; AIRWAY; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; BIOCHEMISTRY; C57BL 6 MOUSE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; EXHALATION; FEMALE; HYPERACTIVITY; INFLAMMATION; KNOCKOUT MOUSE; LUNG COMPLIANCE; LUNG FUNCTION; LUNG LAVAGE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; NOS2 KNOCKOUT MICE; PHYSIOLOGY; PNEUMONIA; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; ARGINASE; ARGININE; ASTHMA; BREATH TESTS; BRONCHIAL HYPERREACTIVITY; BRONCHIAL PROVOCATION TESTS; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; LUNG; LUNG COMPLIANCE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OVALBUMIN; PNEUMONIA; UP-REGULATION;

ANIMALIA; MUS;

EID: 58649121269     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.10.007     Document Type: Article

References (29)

1. Berkowitz D.E., White R., Li D., Minhas K.M., Cernetich A., Kim S., Burke S., Shoukas A.A., Nyhan D., Champion H.C., and Hare J.M. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 108 (2003) 2000-2006
2. Durante W., Johnson F.K., and Johnson R.A. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin. Exp. Pharmacol. Physiol. 34 (2007) 906-911
3. El-Gayar S., Thuring-Nahler H., Pfeilschifter J., Rollinghoff M., and Bogdan C. Translational control of inducible nitric oxide synthase by IL-13 and arginine availability in inflammatory macrophages. J. Immunol. 171 (2003) 4561-4568
4. Endo M., Oyadomari S., Terasaki Y., Takeya M., Suga M., Mori M., and Gotoh T. Induction of arginase I and II in bleomycin-induced fibrosis of mouse lung. Am. J. Physiol. Lung Cell Mol. Physiol. 285 (2003) L313-321
5. Fajardo I., Svensson L., Bucht A., and Pejler G. Increased levels of hypoxia-sensitive proteins in allergic airway inflammation. Am. J. Respir. Crit. Care Med. 170 (2004) 477-484
6. Gotoh T., Araki M., and Mori M. Chromosomal localization of the human arginase ii gene and tissue distribution of its mRNA. Biochem. Biophys. Res. Commun. 233 (1997) 487-491
7. Grody W.W., Dizikes G.J., and Cederbaum S.D. Human arginase isozymes. Isozymes Curr. Top. Biol. Med. Res. 13 (1987) 181-214
8. Hakonarson H., Unnur S., Bjornsdottir U.S., Halapi E., Palsson S., Adalsteinsdottir E., Gislason D., Finnbogason G., Gislason T., Kristjansson K., Arnason T., Birkisson I., Frigge M.L., Kong A., Gulcher J.R., and Stefansson K. A major susceptibility gene for asthma maps to chromosome 14q24. Am. J. Hum. Genet. 71 (2002) 483-491
9. Hjoberg J., Shore S., Kobzik L., Okinaga S., Hallock A., Vallone J., Subramaniam V., De Sanctis G.T., Elias J.A., Drazen J.M., and Silverman E.S. Expression of nitric oxide synthase-2 in the lungs decreases airway resistance and responsiveness. J. Appl. Physiol. 97 (2004) 249-259
10. Kenyon N.J., Bratt J.M., Linderholm A.L., Last M.S., and Last J.A. Arginases I and II in lungs of ovalbumin-sensitized mice exposed to ovalbumin: sources and consequences. Toxicol. Appl. Pharmacol. 230 (2008) 269-275
11. Kenyon N.J., Ward R.W., and Last J.A. Airway fibrosis in a mouse model of airway inflammation. Toxicol. Appl. Pharmacol. 186 (2003) 90-100
12. Kenyon N.J., Gohil K., and Last J.A. Susceptibility to ovalbumin-induced airway inflammation and fibrosis in inducible nitric oxide synthetase-deficient mice: mechanisms and consequences. Toxicol. Appl. Pharmacol. 191 (2003) 2-11
13. Kenyon N.J., and Last J.A. Reversible and irreversible airway inflammation and fibrosis in mice exposed to inhaled ovalbumin. Inflammation Res. 54 (2005) 57-65
14. Kenyon N.J., van der Vliet A., Schock B.C., Okamoto T., McGrew G.M., and Last J.A. Susceptibility to ozone-induced acute lung injury in iNOS-deficient mice. Am. J. Physiol. Lung Cell Mol. Physiol. 282 (2002) L540-545
15. King N.E., Rothenberg M.E., and Zimmermann N. Arginine in asthma and lung inflammation. J. Nutr. 134 (2004) 2830-2836S
16. Lee J., Ryu H., Ferrante R.J., Morris Jr. S.M., and Ratan R.R. Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proc. Natl. Acad. Sci. USA 100 (2003) 4843-4848
17. Levillain O., Balvay S., and Peyrol S. Mitochondrial expression of arginase II in male and female rat inner medullary collecting ducts. J. Histochem. Cytochem. 53 (2005) 533-541
18. Li H., Meininger C.J., Hawker Jr. J.R., Haynes T.E., Kepka-Lenhart D., Mistry S.K., Morris Jr. S.M., and Wu G. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am. J. Physiol. Endocrinol. Metab. 280 (2001) E75-E82
19. Li H., Meininger C.J., Kelly K.A., Hawker Jr. J.R., Morris Jr. S.M., and Wu G. Activities of arginase I and II are limiting for endothelial cell proliferation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282 (2002) R64-R69
20. Li D., Shirakami G., Zhan X., and Johns R.A. Regulation of ciliary beat frequency by the nitric oxide-cyclic guanosine monophosphate signaling pathway in rat airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 23 (2000) 175-181
21. Meurs H., Maarsingh H., and Zaagsma J. Arginase and asthma: novel insights into nitric oxide homeostasis and airway hyperresponsiveness. Trends Pharmacol. Sci. 24 (2003) 450-455
22. Morris C.R., Poljakovic M., Lavrisha L., Machado L., Kuypers F.A., and Morris Jr. S.M. Decreased arginine bioavailability and increased serum arginase activity in asthma. Am. J. Respir. Crit. Care Med. 170 (2004) 148-153
23. Ricciardolo F.L. cNOS-iNOS paradigm and arginase in asthma. Trends Pharmacol. Sci. 24 (2003) 560-561
24. Sarwar G., and Botting H.G. Rapid analysis of nutritionally important free amino acids in serum and organs (liver, brain, and heart) by liquid chromatography of precolumn phenylisothiocyanate derivatives. J. Assoc. Off. Anal. Chem. 73 (1990) 470-475
25. Schuster G.U., Kenyon N.J., and Stephensen C.B. Vitamin A deficiency decreases and high dietary vitamin A increases disease severity in the mouse model of asthma. J. Immunol. 180 (2008) 1834-1842
26. Silkoff P.E., Wakita S., Chatkin J., Ansarin K., Gutierrez C., Caramori M., McClean P., Slutsky A.S., Zamel N., and Chapman K.R. Exhaled nitric oxide after beta2-agonist inhalation and spirometry in asthma. Am. J. Respir. Crit. Care Med. 159 (1999) 940-944
27. Szalai C., Ungvári I., Pelyhe L., Tölgyesi G., and Falus A. Asthma from a pharmacogenomic point of view. Brit. J. Pharmacol. 153 (2008) 1602-1614
28. Vercelli D. Arginase: marker, effector, or candidate gene for asthma?. J. Clin.Invest. 111 (2003) 1815-1817
29. Zimmermann N., King N.E., Laporte J., Yang M., Mishra A., Pope S.M., Muntel E.E., Witte D.P., Pegg A.A., Foster P.S., Hamid Q., and Rothenberg M.E. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J. Clin. Invest. 111 (2003) 1863-1874